Literature DB >> 11222464

Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors.

O E Brodde1, R Büscher, R Tellkamp, J Radke, S Dhein, P A Insel.   

Abstract

BACKGROUND: Recent evidence indicates that certain genotypes of beta(2)-adrenoceptors (AR) may indicate an increased risk of cardiovascular disease or an increased rate of disease progression. Of particular importance, the Thr164Ile polymorphism, which is found in approximately 4% of humans, shows decreased receptor signaling, blunted cardiac response when expressed in transgenic mice, and is associated with a decreased survival rate in patients with congestive heart failure. METHODS AND
RESULTS: In this study, we compared functional activity, ie, chronotropic (heart rate increases) and inotropic (duration of the electromechanical systole) responses to intravenously administered terbutaline, in 6 subjects (4 women and 2 men) who were heterozygous for Thr164Ile with the responses in 12 volunteers (6 women and 6 men) who were homozygous for wild-type (WT) beta(2)-AR (ie, Arg16, Gln27, and Thr164). The beta(2)AR polymorphism significantly affected the dose-response curves for terbutaline-induced inotropic and chronotropic responses: compared with WT individuals, subjects with the Thr164Ile receptor had substantial blunting in maximal increases in heart rate (WT, 29.7+/-3.9 beats/min; Ile164, 20.7+/-1.9 beats/min; P:=0.016) and a shortening of the duration of electromechanical systole (WT, 51.9+/-4.5 ms; Ile164, 37.9+/-4.6 ms; P:=0.02).
CONCLUSIONS: These data show that humans with the Ile164 genotype show blunted cardiac beta(2)-AR responsiveness, which may help explain the decreased survival of patients with this genotype in the setting of congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222464     DOI: 10.1161/01.cir.103.8.1048

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  20 in total

Review 1.  Genetic polymorphisms of adrenergic receptors.

Authors:  E M Garland; I Biaggioni
Journal:  Clin Auton Res       Date:  2001-04       Impact factor: 4.435

Review 2.  Beta-adrenoceptor polymorphisms.

Authors:  K Leineweber; R Büscher; H Bruck; O-E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-28       Impact factor: 3.000

3.  RAAS and adrenergic genes in heart failure: Function, predisposition and survival implications.

Authors:  Alberto J Alves; Nir Eynon; José Oliveira; Ehud Goldhammer
Journal:  World J Cardiol       Date:  2010-07-26

4.  Functional adrenergic receptor polymorphisms and idiopathic orthostatic intolerance.

Authors:  R Winker; A Barth; E Valic; R Maier; W Osterode; A Pilger; H W Rüdiger
Journal:  Int Arch Occup Environ Health       Date:  2005-02-18       Impact factor: 3.015

Review 5.  The genomic architecture of sporadic heart failure.

Authors:  Gerald W Dorn
Journal:  Circ Res       Date:  2011-05-13       Impact factor: 17.367

Review 6.  {beta}-Adrenoceptor gene variation and intermediate physiological traits: prediction of distant phenotype.

Authors:  John H Eisenach; Erica D Wittwer
Journal:  Exp Physiol       Date:  2010-04-09       Impact factor: 2.969

7.  Novel human alpha1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function.

Authors:  Beilei Lei; Daniel P Morris; Michael P Smith; Laura P Svetkey; Mark F Newman; Jerome I Rotter; Thomas A Buchanan; Stephen M Beckstrom-Sternberg; Eric D Green; Debra A Schwinn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-03-10       Impact factor: 3.000

Review 8.  Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.

Authors:  Mario Cazzola; Maria G Matera; Claudio F Donner
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Arginine (CGC) codon targeting in the human prostacyclin receptor gene (PTGIR) and G-protein coupled receptors (GPCR).

Authors:  Jeremiah Stitham; Eric J Arehart; Scott Gleim; Karen Douville; Todd MacKenzie; John Hwa
Journal:  Gene       Date:  2007-04-01       Impact factor: 3.688

Review 10.  Very important pharmacogene summary ADRB2.

Authors:  Augusto A Litonjua; Li Gong; Qing Ling Duan; Jaekyu Shin; Mariellen J Moore; Scott T Weiss; Julie A Johnson; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-01       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.